Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0471-0119 · 1 trial · 1 indication
Number of events
| Arm | Type | Description |
|---|---|---|
| NNC0471-0119 | EXPERIMENTAL | Participants randomised to NNC0471-0119 |
| Faster aspart | ACTIVE_COMPARATOR | Participants randomised to faster aspart. |
| Name | Type | Description |
|---|---|---|
| NNC0471-0119 | DRUG | Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state. |
| Fast-acting insulin aspart | DRUG | Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight, administered subcutaneously (s.c., under the skin) in fasting state. |
Inclusion Criteria: * Male subject or female subject of non-childbearing potential. Non-childbearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months without...
NNC0471-0119 is an investigational small molecule being developed for the treatment of Type 1 Diabetes Mellitus. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
NNC0471-0119 is a small molecule insulin. It is designed to work as an insulin replacement in people with Type 1 Diabetes Mellitus, helping to manage blood glucose levels.
NNC0471-0119 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO.
NNC0471-0119 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency.
NNC0471-0119 has one completed Phase 1 trial, NCT04655690, which studied its safety and how it works in people with Type 1 Diabetes Mellitus. The trial enrolled 48 participants in Austria and was randomized, double-blind, and active-controlled.
NNC0471-0119 is an insulin, specifically a small molecule insulin. It is being studied as a potential treatment for Type 1 Diabetes Mellitus, but it is not the same as other marketed insulin products.